Gilead Sciences Stock Poised for More Upside
Gilead Sciences (GILD) shares have risen approximately 35% since Barron's last recommended them a year ago, driven by a robust portfolio of HIV and oncology medications contributing to stable revenue.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.